After PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 mo

Research output: Contribution to journalComment/debate

Abstract

Question
After percutaneous coronary intervention (PCI) and 3 months of dual-antiplatelet therapy (DAPT), is P2Y12-inhibitor monotherapy noninferior to continued DAPT?
Original languageEnglish
Pages (from-to)JC53
Number of pages1
JournalAnnals of Internal Medicine
Volume171
Issue number10
DOIs
Publication statusPublished - 19 Nov 2019

Keywords

  • randomised controlled trial
  • thrombosis
  • percutaneous coronary intervention
  • Angioplasty
  • Antagonist Monotherapy
  • Dual Antiplatelet Therapy

Fingerprint Dive into the research topics of 'After PCI and 3 mo of DAPT, P2Y12-inhibitor monotherapy was noninferior to DAPT at 12 mo'. Together they form a unique fingerprint.

Cite this